Stocktoria
Aquestive Therapeutics, Inc. AQST
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-07-25
Aquestive Therapeutics, Inc. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.5M | $57.6M | $50.6M | $47.7M | $50.8M | $45.8M | $52.6M | $67.4M | $66.9M |
| R&D expense | $17.2M | $20.3M | $13.1M | $17.5M | $17.0M | $19.9M | $20.6M | $23.1M | $22.1M |
| SG&A expense | $79.8M | $50.2M | $31.8M | $52.9M | $53.5M | $55.9M | $64.3M | $72.3M | $25.1M |
| Operating income | -$71.1M | -$30.8M | -$15.1M | -$42.1M | -$34.7M | -$42.9M | -$52.7M | -$48.9M | -$113,000 |
| Interest expense | — | — | $6.3M | $6.6M | $10.0M | $11.1M | $9.3M | $7.7M | $7.7M |
| Income tax | $0 | -$14,000 | $245,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$83.8M | -$44.1M | -$7.9M | -$54.4M | -$70.5M | -$55.8M | -$66.2M | -$61.4M | -$8.9M |
| EPS (diluted) | $-0.78 | $-0.51 | $-0.13 | $-1.12 | $-1.85 | $-1.66 | — | — | — |
| Operating cash flow | -$52.4M | -$35.8M | -$6.4M | -$9.8M | -$33.0M | -$45.5M | -$60.2M | -$13.0M | $5.8M |
| Free cash flow | -$53.0M | -$35.9M | -$7.4M | -$10.8M | -$33.9M | -$46.0M | -$60.9M | -$14.8M | $3.8M |
| Cash & equivalents | $121.2M | $71.5M | $23.9M | $27.3M | $28.0M | $31.8M | $49.3M | $60.6M | $17.4M |
| Inventory | $6.2M | $6.0M | $6.8M | $5.8M | $4.0M | $2.5M | $2.9M | $5.4M | $4.0M |
| Total assets | $160.4M | $101.4M | $57.4M | $57.1M | $62.0M | $62.9M | $78.5M | $86.9M | $43.1M |
| Total liabilities | $194.1M | $161.6M | $163.9M | $175.6M | $144.1M | $111.4M | $84.6M | $76.8M | $69.6M |
| Shareholders' equity | -$33.7M | -$60.2M | -$106.5M | -$118.6M | -$82.1M | -$48.5M | -$6.1M | $10.1M | -$26.5M |
Growth · year-over-year · Revenue CAGR -5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -22.6% | +13.8% | +6.1% | -6.2% | +10.9% | -12.8% | -22.0% | +0.8% | — |
| Free cash flow growth | — | — | — | — | — | — | — | -494.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.